
    
      This is an open-label Phase Ib-II trial to evaluate the safety and efficacy of GX-188E (IM
      administration using Ichor TDS-IM device) + pembrolizumab (P) in patients with advanced
      HPV-16+ or HPV-18+ cervical cancer.
    
  